Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The supply update likely spells the end of widespread GLP-1 compounding in the U.S., which became an immensely popular avenue for patients to access weight loss drugs while Novo and Lillys branded products were in shortage
The Saxagliptin Assessment of Vascular Outcomes (SAVOR-TIMI 53) study is a similar study in 12,000 patients comparing saxagliptin with placebo in diabetic patients with high cardiovascular risk
*Votre adresse email sera utilise par Digital Prisma Players pour vous envoyer votre newsletter contenant des offres commerciales personnalises
Payers should collaborate with plan sponsors, PBMs, manufacturers and providers to expand GLP-1 coverage: Payers have a key role in realizing GLP-1 cost savings as well as ensuring equitable, affordable access and quality of care by collaborating with PBMs, GLP-1 manufacturers and plan sponsors to expand GLP-1 coverage while driving down costs
US$ 29.49
US$ 21.72
US$ 29.23
US$ 24.47
US$ 24.72
US$ 20.41
US$ 23.34
US$ 24.07
US$ 23.62
US$ 28.20
US$ 28.91
US$ 23.68
US$ 27.74
